Pharmacologic management of atrial fibrillation: Established and emerging options

Journal of Managed Care Pharmacy

Volumn 15, Issue 6 SUPPL. B, 2009, Pages

  Kalus, James S ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; DABIGATRAN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; FLECAINIDE; HYDROCHLOROTHIAZIDE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; RIVAROXABAN; SIMVASTATIN; SOTALOL; TEDISAMIL; UNINDEXED DRUG; VERAPAMIL; VERNAKALANT; WARFARIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AGE DISTRIBUTION; ANTICHOLINERGIC EFFECT; ANTICOAGULANT THERAPY; ASTHMA; BLEEDING TENDENCY; BRADYCARDIA; CARDIAC PATIENT; CARDIOVERSION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; CONGESTIVE HEART FAILURE; CORNEA DISEASE; CREATININE BLOOD LEVEL; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG FATALITY; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG UTILIZATION; DYSGEUSIA; EYE DISEASE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER TOXICITY; LOADING DRUG DOSE; LUNG FIBROSIS; NEUROPATHY; OPTIC NEURITIS; OUTPATIENT; PARESTHESIA; PHARMACEUTICAL CARE; PHOTOSENSITIVITY; QT PROLONGATION; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SINUS RHYTHM; SKIN DISCOLORATION; SNEEZING; STROKE; THYROID DISEASE; TORSADE DES POINTES; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VENOUS THROMBOEMBOLISM; XEROSTOMIA;

ANTI-ARRHYTHMIA AGENTS; ANTICOAGULANTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; DRUG MONITORING; HUMANS;

EID: 70349601198     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2009.15.s6-b.10     Document Type: Review

References (67)

1. Fuster V, Rydén LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-354. Available at: http://circ.ahajournals.org/cgi/reprint/114/ 7/e257. Accessed July 23, 2009.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70. Available at: http://jama.ama-assn.org/cgi/reprint/285/22/2864. Accessed July 23, 2009. (Pubitemid 32537350)
3. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008;133(6 Suppl):546S-92S. Available at: http://www.chestjournal.org/content/133/6-suppl/546S.full.pdf+html. Accessed July 23, 2009.
4. Wyse DG, Waldo AL, DiMarco JP, et al.; AFFIRM Investigators. A comparison of rate control with rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347(23):1825-33. Available at: http://content.nejm.org/cgi/ reprint/347/23/1825.pdf. Accessed July 23, 2009.
5. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004;43(2):241-47. Available at: http://content.onlinejacc.org/cgi/reprint/43/2/ 241.pdf. Accessed July 23, 2009. (Pubitemid 38201151)
6. Grönefeld GC, Lilienthal J, Kuck KH, Hohnloser SH, Pharmacologic Intervention in Atrial Fibrillation (PIAF) Study investigators. Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation. Results from a prospective randomized study. Eur Heart J. 2003;24(15):1430-36. Available at: http://eurheartj.oxfordjournals.org/cgi/ reprint/24/15/1430. Accessed July 23, 2009.
7. Coyne KS, Paramore C, Grandy S, Mercader M, Reynolds M, Zimetbaum P. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health. 2006;9(5):348-56. 8. Choudhry NK, Zagorski B, Avorn J, et al. Comparison of the impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial on prescribing patterns: a time-series analysis. Ann Pharmacother. 2008;42(11):1563-1572 (Pubitemid 44337788)
8. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358(25):2667-77. Available at: http://content.nejm.org/cgi/reprint/358/25/2667.pdf. Accessed July 23, 2009. (Pubitemid 351860859)
9. King DE, Dickerson LM, Sack JL. Acute management of atrial fibrillation: Part I. Rate and rhythm control. Am Fam Physician. 2002;66(2):249-56. Available at: http://www.aafp.org/afp/20020715/249.pdf. Accessed July 23, 2009.
10. Tabery S, Bouwels L, Uijen GJH, Uppelschoten A, Verheugt FWA. Factors influencing immediate and long-term outcome of electrical cardioversion of persistent atrial fibrillation and flutter. Neth Heart J. 2001;9(1):16-22. Available at: http://www.pubmedcentral.nih.gov/picrender.fcgi?artid= 2499578&blobtype=pdf. Accessed July 23, 2009.
11. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJ. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol. 1999;84(9A):147R-51R.
12. Hiatt WR, Lincoff A, Harrington RA. Acute pharmacological conversion of atrial fibrillation to sinus rhythm: is short-term therapy worth it? A report from the December 2007 meeting of the Cardiovascular and Renal Drugs Advisory Committee of the Food and Drug Administration. Circulation. 2008;117(22):2956- 57. Available at: http://circ.ahajournals.org/cgi/reprint/117/22/2956. Accessed July 26, 2009.
13. Norpace [package insert]. Chicago, IL: G.D. Searle LLC; September 2001. http://www.pfizer.com/files/products/uspi-norpace.pdf. Accessed July 23, 2009.
14. McEvoy GK, ed. Quinidine gluconate/quinidine sulfate. In: AHFS Drug Informafion 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:1652-1657
15. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-412
16. Rythmol [package insert]. Liberty Corner, NJ: Reliant Pharmaceuticals, Inc.; September 2004. Available at: http://us.gsk.com/products/assets/us- rythmol.pdf. Accessed July 23, 2009.
17. McEvoy GK, ed. Propafenone hydrochloride. In: AHFS Drug Information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:1671-1682
18. Fang MC, Stafford RS, Ruskin JN, Singer DE. National trends in antiarrhythmic and antithrombotic medication use in atrial fibrillation. Arch Intern Med. 2004;164(1):55-60. Available at: http://archinte.ama-assn.org/cgi/ reprint/164/1/55. Accessed July 23, 2009.
19. Cordarone [package insert]. Philadelphia, PA: Wyeth Pharmaceuticals Inc.; May 2009. Available at: http://www.wyeth.com/content/showlabeling.asp?id=93. Accessed July 23, 2009.
20. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333(2):77-82. Available at: http://content.nejm.org/cgi/reprint/333/2/77. pdf. Accessed July 23, 2009.
21. Massie BM, Fisher SG, Radford M, et al., for the CHF-STAT Investigators. Effect of amiodarone on clinical status and left ventricular function in patients with congestive heart failure. Circulation. 1996;93(12):2128-34. Available at: http://circ.ahajournals.org/cgi/content/full/93/12/2128. Accessed July 23, 2009.
22. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet. 1994;344(8921):493-498 (Pubitemid 24261565)
23. Bardy GH, Lee KL, Mark DB, et al for the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225-37. Available at: http://content.nejm.org/cgi/reprint/352/3/225. pdf. Accessed July 23, 2009.
24. McEvoy GK, ed. Amiodarone hydrochloride. In: AHFS Drug Information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:1682-1697
25. Yamreudeewong W, DeBisschop M, Martin LG, Lower DL. Potentially significant drug interactions of class III antiarrhythmic drugs. Drug Saf. 2003;26(6):421-438 (Pubitemid 36560714)
26. Betapace AF [package insert]. Wayne, NJ: Bayer Healthcare Pharmaceuticals; April 2007. Available at: http://berlex.bayerhealthcare.com/ html/products/pi/BetapaceAF-Pl.pdf. Accessed July 23, 2009.
27. McEvoy GK, ed. Sotalol hydrochloride. In: AHFS Drug Information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:1928-34.
28. Pedersen OD, Brendorp B, Elming H, Pehrson S, Køber L, Torp-Pedersen C. Does conversion and prevention of atrial fibrillation enhance survival in patients with left ventricular dysfunction? Evidence from the Danish Investigations of Arrhythmia and Mortality ON Dofetilide/(DIAMOND) study. Card Electrophysiol Rev. 2003;7(3):220-224 (Pubitemid 38256102)
29. McEvoy GK, ed. Dofetilide. In: AHFS Drug Information 2009. Bethesda, MD: American Society of Health-System Pharmacists; 2009:1697-1698
30. Torp-Pedersen C, Møller M, Block-Thomsen PE, et al. Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmia and Mortality on Dofetilide Study Group. N Engl J Med. 1999;341(12):857-65. Available at: http://content.nejm.org/cgi/reprint/341/ 12/857.pdf. Accessed July 23, 2009.
31. Kalus JS, Mauro VF. Dofetilide: a class III-specific antiarrhythmic agent. Ann Pharmacother. 2000;34(1):44-46
32. Tikosyn [package insert]. New York, NY: Pfizer Labs; March 2004. http://www.tikosyn.com/pdf/Pl-tikosyn.pdf. Accessed July 23, 2009.
33. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007 Oct 17;(4):CD005049.
34. Kochiadakis GE, Igoumenidis NE, Hamilos ME, et al. Sotalol versus propafenone for long-term maintenance of normal sinus rhythm in patients with recurrent symptomatic atrial fibrillation. Am J Cardiol. 2004;94(12):1563-1566 (Pubitemid 40268465)
35. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352(18):1861-72. Available at: http://content.nejm.org/cgi/reprint/352/18/1861.pdf. Accessed July 23, 2009.
36. Kochiadakis GE, Igoumenidis NE, Hamilos MI, et al. Long-term maintenance of normal sinus rhythm in patients with current symptomatic atrial fibrillation: amiodarone vs. propafenone, both in low doses. Chest. 2004;125(2):377-83. Available at: http://www.chestjournal.org/content/125/2/377.full.pdf+html. Accessed July 23, 2009.
37. Alboni P, Botto GL, Baldi N, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med. 2004;351(23):2384-91. Available at: http://content.nejm.org/cgi/reprint/ 351/23/2384.pdf. Accessed July 23, 2009.
38. Sun W, Sarma JS, Singh BN. Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation. 1999;100(22):2276-81. Available at: http://circ.ahajournals.org/cgi/reprint/100/22/2276. Accessed July 26, 2009.
39. Laughlin JC, Kowey PR. Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(11):1220-1226
40. Dale KM, White CM. Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. Ann Pharmacother. 2007;41(4):599-605. (Pubitemid 46625482)
41. Damy T, Pousset F, Caplain H, Hulot JS, Lechat P. Pharmacokinetic and pharmacodynamic interactions between metoprolol and dronedarone in extensive and poor CYP2D6 metabolizers healthy subjects. Fundam Clin Pharmacol. 2004;18(1):113-123 (Pubitemid 38200927)
42. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357(10):987-99. Available at: http://content.nejm.org/cgi/reprint/357/10/ 987.pdf. Accessed July 23, 2009.
43. Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008;358(25):2678-87. Available at: http://content.nejm.org/cgi/reprint/358/25/ 2678.pdf. Accessed July 23, 2009. (Pubitemid 351860860)
44. Hohnloser SH, Crijns HJ, van Eickels M, et al., for the ATHENA Investigators. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009;360(7):668-78. Available at: http://content.nejm.org/cgi/reprint/360/7/668.pdf. Accessed July 26, 2009.
45. sanofi-aventis. DIONYSOS study results showed the respective profiles of dronedarone and amiodarone. December 23, 2008. Available at: http://en.sanofi-aventis.com/press/press-releases/2008/ppc-23625.asp. Accessed July 23, 2009.
46. Zimetbaum PJ. Dronedarone for atrial fibrillation - an Odyssey. N Engl J Med. 2009;360(18):1811-1813
47. Anonymous. FDA advisory committee recommends approval of Multaq (dronedarone). Medical News Today. March 19, 2009. Available at: http://www.medicalnewstoday.com/articles/142834.php. Accessed July 26, 2009.
48. U.S. Food and Drug Administration. FDA approves Multaq to treat heart rhythm disorder. July 2, 2009. Available at: http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm170276.htm. Accessed July 31, 2009.
49. Cheng JW. Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008;42(4):533-542
50. Roy D, Pratt CM, Torp-Pedersen D, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation. 2008;117:1518-25. Available at: http://circ.ahajournals.org/cgi/content/full/117/12/1518. Accessed July 23, 2009.
51. Wood S. Advisory panel recommends approval of vernakalant for AF. December 12, 2007. Available at: http://www.theheart.org/article/833263.do. Accessed April 8, 2009.
52. Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, et al. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: Results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial. J Am Coll Cardiol. 2004;43(7):1211-16. Available at: http://content.onlinejacc.org/cgi/reprint/43/7/1211. Accessed July 23, 2009.
53. Pritchett EL Kowey P, Connolly S, et al. Antiarrhythmic efficacy of azimilide in patients with atrial fibrillation. Maintenance of sinus rhythm after conversion to sinus rhythm. Am Heart J. 2006;151(5):1043-1049
54. Lombardi F, Borggrefe M, Ruzyllo W, Luderitz B; A-COMET- II Investigators. Azimilide vs. placebo and sotalol for persistent atrial fibrillation: the A-COMET-II (Azimilide-CardiOversion MaintEnance Trial-II) trial. Eur Heart J. 2006;27(18):2224-31. Available at: http://eurheartj. oxfordjournals.org/cgi/reprint/27/18/2224. Accessed July 23, 2009. (Pubitemid 44412838)
55. Kerr CR, Connolly SJ, Kowey P, et al. Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart disease. Am J Cardiol. 2006;98(2):215-218 (Pubitemid 43975503)
56. Camm AJ, Savelieva I. New antiarrhythmic drugs for atrial fibrillation: focus on dronedarone and vernakalant. J Interv Cardiol Electrophys. 2008;23(1):7-14.
57. Kalus JS, Coleman CI, White CM. The impact of suppressing the renin-angiotensin system on atrial fibrillation. J Clin Pharmacol. 2006;46(1):21-28. (Pubitemid 43024117)
58. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999;100(4):376-80. Available at: http://circ.ahajournals.org/cgi/reprint/100/4/376. Accessed July 23, 2009. (Pubitemid 29362407)
59. Vermes E, Tardif JC, Bourassa MG, et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003;107(23):2926-31. Available at: http://circ.ahajournals.org/ cgi/reprint/107/23/2926. Accessed July 26, 2009. (Pubitemid 36314413)
60. Maggioni AP, Latini R, Carson PE, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548-557 (Pubitemid 40585420)
61. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-19. Available at: http://content.onlinejacc.org/cgi/reprint/45/5/712.pdf. Accessed July 23, 2009. (Pubitemid 40282586)
62. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI. Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail. 1995;1(5):355-363
63. Madrid AH, Bueno MG, Rebollo JM, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106(3):331-36. Available at: http://circ.ahajournals.org/cgi/reprint/106/3/331. Accessed July 23, 2009.
64. Madrid AH, Marin IM, Cervantes CE, et al. Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst. 2004;5(3):114-20. Available at: http://jra.sagepub.com/cgi/reprint/5/3/114. Accessed July 23, 2009.
65. Ueng KC, Tsai TP, Yu WC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24(23):2090-98. Available at: http://eurheartj.oxfordjournals.org/cgi/ reprint/24/23/2090. Accessed July 23, 2009.
66. Turpie AG. New oral anticoagulants in atrial fibrillation. Eur Heart J. 2008;29(2):155-65. Available at: http://eurheartj.oxfordjournals.org/cgi/ reprint/29/2/155. Accessed July 23, 2009.
67. Walker EP. Rivaroxaban recommended for approval by FDA advisory panel. Medpage Today. March 19, 2009. Available at: http://www.medpagetoday.com/ ProductAlert/Prescriptions/13353. Accessed July 24, 2009.